“pfizer” Archives

in
Entry Author Date Location
Elanco IPO Raises $1.5B as the Animal Health Biz Spins Off from Lilly 09/20/18 Indiana
Allogene Files for IPO to Fund Cancer Cell Therapy Clinical Trials 09/14/18 San Francisco
Bio Roundup: A Gene Editing 1st, China Rises, Schenkein Steps Away 09/07/18 National
On Cusp of Gene Therapy Clinical Trial, 4D Molecular Reels In $90M 09/05/18 San Francisco
Bio Roundup: Pfizer’s Rare Results, U.K.’s CAR-T No, IPO Go-Go & More 08/31/18 National
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug 08/30/18 Boston
Eyeing Approval, Pfizer Touts Tafamidis Study, but Details Lacking 08/27/18 New York
Foxconn, Doyenne, Socialeads & More: This Week’s WI Watchlist 08/24/18 Wisconsin
Bio Roundup: EpiPen Shortage, Bluebird’s Bet, Biotech IPOs & More 08/24/18 National
Exact Sciences Shares Rise After Company Unveils Pfizer Partnership 08/22/18 Wisconsin
Pain Drug Race Continues as Regeneron Posts Early Phase 3 Results 08/16/18 New York
With BioNTech Deal, Pfizer Becomes Latest to Bet on mRNA Vaccines 08/16/18 New York
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug 08/10/18 Boston
Elanco’s IPO Would Free Eli Lilly to Focus on Pharmaceuticals 08/03/18 Indiana
Bio Roundup: Alnylam’s Moment, Read on Rebates, Skinny Plans & More 08/03/18 National
OUTBio, a Biopharma LGBTQ Group, Grows Fast & Ponders Its Future 07/26/18 Boston
Bio Roundup: Drug Prices, CRISPR Caveats, Rubius IPO Pop & More 07/20/18 National
With $45M, HotSpot Takes Drug Research to New Biological Real Estate 07/17/18 Boston
Bio Roundup: Pfizer’s Prices, Novartis Cuts, Gene Therapy Guide & More 07/13/18 National
Down the Stretch: Akcea, Alnylam Face Reality Checks as FDA Dates Loom 07/06/18 Boston
Sarepta’s Data Are First in Rush for Duchenne Gene Therapy 06/19/18 Boston
As Sarepta Preps Data, FDA Lifts Hold on Solid’s Duchenne Gene Therapy 06/18/18 Boston
Bio Roundup: Brii Does China, Hemophilia Updates, Right to Try & More 05/25/18 National
Brii Biosciences Debuts with a China Pharma Strategy Backed by $260M 05/24/18 Raleigh Durham
Bio Roundup: ASCO Abstracts, Migraine Drug Prices & “Blueprint” Fallout 05/18/18 National
Verdine Picks Backers For FogPharma’s $66M Round, Keeping Firm Control 05/16/18 Boston
Rapamycin Holdings Plans Tests of Old Immune Drug in Prostate Cancer 05/09/18 Texas
FDA Panel Splits on Lilly Arthritis Drug, Backs Lower of Two Doses 04/23/18 Indiana
With Alzheimer’s Failure, vTv Fares No Better Than Old Partner Pfizer 04/09/18 Raleigh Durham
Conatus Pharma’s Liver Disease Drug Flunks First Phase 2 Test 04/05/18 San Diego
Page 1 of 28 next page »